Abstract:Methionine Aminopeptidases MetAPs are divalent-cofactor dependent enzymes that are responsible for the cleavage of the initiator Methionine from the nascent polypeptides. MetAPs are classified into two isoforms: namely, MetAP1 and MetAP2. Several studies have revealed that MetAP2 is upregulated in various cancers, and its inhibition has shown to suppress abnormal or excessive blood vessel formation and tumor growth in model organisms. Clinical studies show that the natural product fumagillin, and its analogs are potential inhibitors of MetAP2. However, due to their poor pharmacokinetic properties and neurotoxicities in clinical studies, their further developments have received a great setback. Here, we apply structure-based virtual screening and molecular dynamics methods to identify a new class of potential inhibitors for MetAP2. We screened Otava's Chemical Library, which consists of about 3 200 000 tangible-chemical compounds, and meticulously selected the top 10 of these compounds based on their inhibitory potentials against MetAP2. The top hit compounds subjected to ADMET predictor using 3 independent ADMET prediction programs, were found to be drug-like. To examine the stability of ligand binding mode, and efficacy, the unbound form of MetAP2, its complexes with fumagillin, spiroepoxytriazole, and the best promising compounds compound-3369841 and compound-3368818 were submitted to 100 ns molecular dynamics simulation. Like fumagillin, spiroepoxytriazole, and both compound-3369841 and compound-3368818 showed stable binding mode over time during the simulations. Taken together, these uninherited-fumagillin compounds may serve as new class of inhibitors or provide scaffolds for further optimization towards the design of more potent MetAP2 inhibitors -development of such inhibitors would be essential strategy against various cancer types.

Beta-aminoketones as prodrugs for selective irreversible inhibitors of type-1 methionine aminopeptidases

Synthesis of barbiturate-based methionine aminopeptidase-1 inhibitors

Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1

Identification of promising methionine aminopeptidase enzyme inhibitors: A combine study of comprehensive virtual screening and dynamics simulation study

Identification of potential inhibitors of human methionine aminopeptidase (type II) for cancer therapy: Structure-based virtual screening, ADMET prediction and molecular dynamics studies

Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells

Structural basis for the functional differences between type I and type II human methionine aminopeptidases

Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Discovery, identification, and characterization of candidate pharmacodynamic markers of methionine aminopeptidase-2 inhibition

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Ionic immobilization, diversification, and release: application to the generation of a library of methionine aminopeptidase inhibitors

Inhibition of Insulin-Regulated Aminopeptidase by Imidazo [1,5-α]pyridines—Synthesis and Evaluation

Highly Selective Aza-Nitrile Inhibitors for Cathepsin K, Structural Optimization and Molecular Modeling

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting

Synthesis and evaluation of enzyme inhibition by novel TT01001 derivatives as monoamine oxidase B inhibitors

Structural analysis of bengamide derivatives as inhibitors of methionine aminopeptidases

Mechanisms of allosteric inhibition of Insulin-Regulated Aminopeptidase

Novel, tightly structurally related N-myristoyltransferase inhibitors display equally potent yet distinct inhibitory mechanisms

Stabilization of the open conformation οf Insulin-Regulated Aminopeptidase by a novel substrate-selective small molecule inhibitor